- Home
- TWLO vs ROIV Comparison
TWLO vs ROIV Comparison
Compare TWLO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TWLO | ROIV |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 28.7B |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TWLO | ROIV |
|---|---|---|
| Price | $211.91 | $39.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 31 | 13 |
| Target Price | ★ $268.37 | $50.64 |
| AVG Volume (30 Days) | 2.6M | ★ 7.7M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.82 | N/A |
| EPS | ★ 8.25 | N/A |
| Revenue | ★ $399,020,000.00 | $8,260,000.00 |
| Revenue This Year | $19.79 | $1,827.44 |
| Revenue Next Year | $11.52 | $196.90 |
| P/E Ratio | $25.71 | ★ N/A |
| Revenue Growth | ★ 43.88 | N/A |
| 52 Week Low | $105.00 | $19.96 |
| 52 Week High | $308.40 | $42.50 |
Technical Indicators
Market Signals| Indicator | TWLO | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 56.04 |
| Support Level | $179.80 | $33.11 |
| Resistance Level | $237.23 | $42.50 |
| Average True Range (ATR) | 12.40 | 1.49 |
| MACD | -0.80 | 0.38 |
| Stochastic Oscillator | 38.63 | 55.76 |
Price Performance
Historical ComparisonAbout TWLO Twilio Inc.
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.